✦ LIBER ✦

Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells

✍ Scribed by Saar Shapira; Galit Granot; Rahav Mor-Tzuntz; Pia Raanani; Orit Uziel; Meir Lahav; Ofer Shpilberg

Book ID: 116335909
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 867 KB
Volume: 323
Category: Article
ISSN: 0304-3835
DOI: 10.1016/j.canlet.2012.04.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-Generation Tyrosine Kinase Inhibi

Second-Generation Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

✍ Roy S. Herbst 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 58 KB

Protein tyrosine kinase inhibitor, genis

Protein tyrosine kinase inhibitor, genistein, enhances apoptosis and cell cycle arrest in K562 cells treated with γ-irradiation

✍ Konstantinos T. Papazisis; Dimitra Zambouli; Ourania T. Kimoundri; Emmanuel S. P 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 400 KB

Second-generation epidermal growth facto

Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer

✍ Mukherji, Deborah; Spicer, James 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 252 KB

Sodium Butyrate Induces Tyrosine Phospho

Sodium Butyrate Induces Tyrosine Phosphorylation and Activation of MAP Kinase (ERK-1) in Human K562 Cells

✍ Juan A. Rivero; Samuel E. Adunyah 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 182 KB

The tyrosine protein kinase inhibitor ge

The tyrosine protein kinase inhibitor genistein reduces tnfa-induced plasminogen activator inhibitor-1 transcription in endothelial cells

✍ Victor W.M. van Hinsbergh; Mario Vermeer; Pieter Koolwijk; Jos Grimbergen; Teaic 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Second-generation tyrosine kinase inhibi

Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia : Before or after imatinib?

✍ Ayalew Tefferi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Imatinib should continue to be the front‐line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second‐generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.